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Combination therapy of carbon-ion irradiation 
and dendritic cell immunotherapy in mouse lung 
metastatic model
Objectives  The carbon-ion C-ion  radiotherapy 
RT  which is one of RT is effective in resistance tumor 
to the conventional RT because of its physics and biolog-
ical characters, and excellent therapy results are ob-
tained. However, metastasis control is one of the im-
portant issues in C-ion RT although local tumor is 
controllable. Therefore, we examined the possibility of 
control of metastasis by the combined therapy with C-
ion. In this study, we focused the combined therapy of 
C-ion irradiation and dendritic cell DC  immunothera-
py and examined the effects of this treatment in the 
mouse lung metastatic model.
Methods The mouse carcinoma cell lines NR-S1, 
LLC, LM8  inoculated into the legs of C3H/He or 
C57BL/6J  mice were irradiated with a single dosage of 
carbon-ion 6 Gy or 2 Gy, 290 MeV/nucleon, 6 cm 
SOBP . At 36 hours after irradiation, DCs were inject-
ed into the mice. The numbers of lung metastasis were 
evaluated using pathological observations. 
Results  We established the mouse metastasis model 
using squamous carcinoma cell line NR-S1, lung cancer 
cell line, LLC, and osteosarcoma cell line, LM8. Un-
der conditions that there are no signi cant effects by the 
treatments on the growth of transplanted tumors, the 
number of lung metastasis was signi cantly decreased by 
the combined therapy. 
Conclusions  Our present results demonstrated that 
combined therapy of C-ion irradiation and DC immuno-
therapy was effective in repression of lung metastasis 
and might be adapted to treatment of various kinds of tu-
mor metastasis.
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